Phase 2 Interstitial Lung Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older
- You are willing and able to give your consent to participate in the study
- You have been diagnosed with either fibrotic hypersensitivity pneumonitis or idiopathic pulmonary fibrosis (two types of scarring lung disease), and your doctor at UW Health has determined you need to start, change, or add a new treatment (Group A)
- You have been diagnosed with either of these scarring lung conditions, but your doctor at UW Health has determined your condition is currently stable and no changes to your treatment are needed (Group B)
- You were originally in the stable group (Group B) but at a later check-up your doctor determined you now need to start, change, or add a treatment (Crossover group)
- You are willing and able to have a combined PET/MRI scan (a type of detailed imaging)
- If you need mild anti-anxiety medication taken by mouth to help with the scan, you may still be eligible, as long as you have your own prescription for it, you give your consent before taking it, and you bring someone to drive you to and from the visit
Who may not be able to join:
- You are unable or unwilling to give your consent to take part in the study
- You are currently pregnant
- You have a medical reason why you cannot safely have a PET/MRI scan
- You have severely reduced kidney function (confirm with trial site), which may mean the scan is done without contrast dye; you will not be automatically excluded but the imaging approach may be adjusted
- You need intravenous (IV) sedation in order to have a scan
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ali Pirasteh, MD, University of Wisconsin, Madison
Phone: 608-282-8349
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in FAPI uptake
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.